Toll-like receptor 4 activation in cancer progression and therapy

Alja Oblak, Roman Jerala, Alja Oblak, Roman Jerala

Abstract

Cancer immunotherapy has been the focus of intense research since the late 19th century when Coley observed that bacterial components can contribute to cancer regression by eliciting an antitumor immune response. Successful activation and maturation of tumor-specific immune cells is now known to be mediated by bacterial endotoxin, which activates Toll-like receptor 4 (TLR4). TLR4 is expressed on a variety of immune as well as tumor cells, but its activation can have opposing effects. While TLR4 activation can promote antitumor immunity, it can also result in increased tumor growth and immunosuppression. Nevertheless, TLR4 engagement by endotoxin as well as by endogenous ligands represents notable contribution to the outcome of different cancer treatments, such as radiation or chemotherapy. Further research of the role and mechanisms of TLR4 activation in cancer may provide novel antitumor vaccine adjuvants as well as TLR4 inhibitors that could prevent inflammation-induced carcinogenesis.

Figures

Figure 1
Figure 1
TLR4/MD-2 receptor complex recognizes and binds endotoxin. (a) MD-2 (shown in blue ribbons) is a soluble protein with a large hydrophobic pocket that directly binds bacterial endotoxin (red). One of the acyl chains of endotoxin (yellow) remains outside the hydrophobic pocket and mediates crucial interactions with TLR4 that bind the TLR4/MD-2 heterodimer together. Left: direct view of the MD-2 hydrophobic pocket. Right: side view showing the protruding endotoxin acyl chain. (b) The TLR4/MD-2/endotoxin heterodimer. Only the extracellular domains of TLR4 whose crystal structures were determined are shown [16].
Figure 2
Figure 2
TLR4 signaling in cancer—a struggle of antitumor immunity against cancer proliferation and immune evasion. TLR4 signaling on immune cells can enhance anti-tumor immunity by different mechanisms, including IL-12 or IFNγ upregulation and promotion of DC maturation and function (left side of the figure, depicted in green). On the other hand, TLR4 signaling on tumor cells can increase their tumorigenic potential (right side of the figure, depicted in red).

References

    1. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. Journal of Leukocyte Biology. 2002;71(6):907–920.
    1. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Current Opinion in Immunology. 1998;10(5):564–572.
    1. Kawai T, Akira S. TLR signaling. Cell Death and Differentiation. 2006;13(5):816–825.
    1. Schreibelt G, Tel J, Sliepen KHEWJ, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunology, Immunotherapy. 2010;59(10):1573–1582.
    1. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(18):7048–7053.
    1. Sutmuller RPM, den Brok MHMGM, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. Journal of Clinical Investigation. 2006;116(2):485–494.
    1. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Current Opinion in Immunology. 2007;19(1):39–45.
    1. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research. 2005;65(12):5009–5014.
    1. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research. 2006;66(7):3859–3868.
    1. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Research. 2007;67(21):10519–10527.
    1. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988;52(2):269–279.
    1. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86(6):973–983.
    1. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. Journal of Experimental Medicine. 1999;189(11):1777–1782.
    1. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. Journal of Biological Chemistry. 2001;276(41):38044–38051.
    1. Resman N, Vašl J, Oblak A, et al. Essential roles of hydrophobic residues in both MD-2 and Toll-like receptor 4 in activation by endotoxin. Journal of Biological Chemistry. 2009;284(22):15052–15060.
    1. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191–1195.
    1. Björkbacka H, Fitzgerald KA, Huet F, et al. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiological Genomics. 2005;19:319–330.
    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
    1. Grauer OM, Molling JW, Bennink E, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. Journal of Immunology. 2008;181(10):6720–6729.
    1. Qian Y, Deng J, Xie H, et al. Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. Journal of Cancer Research and Clinical Oncology. 2009;135(3):379–386.
    1. Yang H, Zhou H, Feng P, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. Journal of Experimental and Clinical Cancer Research. 2010;29(1, article 92)
    1. Tang XY, Zhu YQ, Wei B, Wang H. Expression and functional research of TLR4 in human colon carcinoma. American Journal of the Medical Sciences. 2010;339(4):319–326.
    1. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Research. 2009;29(7):2473–2478.
    1. Szczepański M, Stelmachowska M, Stryczyński Ł, et al. Assessment of expression of Toll-like receptors 2, 3 and 4 in laryngeal carcinoma. European Archives of Oto-Rhino-Laryngology. 2007;264(5):525–530.
    1. Molteni M, Marabella D, Orlandi C, Rossetti C. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Letters. 2006;235(1):75–83.
    1. Goto Y, Arigami T, Kitago M, et al. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Molecular Cancer Therapeutics. 2008;7(11):3642–3653.
    1. Hassan F, Islam S, Tumurkhuu G, et al. Intracellular expression of Toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer. 2006;6, article 281
    1. Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28(49):4353–4363.
    1. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunology, Immunotherapy. 2009;58(9):1375–1385.
    1. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends in Immunology. 2003;24(6):302–306.
    1. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. Journal of Immunology. 2004;173(6):3844–3854.
    1. Sun R, Tian Z, Kulkarni S, Gao B. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. Journal of Immunology. 2004;172(9):5648–5655.
    1. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental Immunology. 2010;2010:9 pages. Article ID 832454.
    1. Nishioka Y, Wen H, Mitani K, et al. Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide. Journal of Leukocyte Biology. 2003;73(5):621–629.
    1. Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WMF. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. Journal of Experimental Medicine. 1998;188(9):1603–1610.
    1. Pei Z, Lin D, Song X, Li H, Yao H. TLR4 signaling promotes the expression of VEGF and TGFβ1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cellular Immunology. 2008;254(1):20–27.
    1. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Michel-Schmidt R, Kirkpatrick CJ. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. International Journal of Molecular Medicine. 2007;20(1):21–29.
    1. Kanczkowski W, Tymoszuk P, Ehrhart-Bornstein M, Wirth MP, Zacharowski K, Bornstein SR. Abrogation of TLR4 and CD14 expression and signaling in human adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism. 2010;95(12):E421–E429.
    1. González-Reyes S, Marín L, González L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10, article 665
    1. Schmaußer B, Andrulis M, Endrich S, Müller-Hermelink H-K, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. International Journal of Medical Microbiology. 2005;295(3):179–185.
    1. Zhang YB, He FL, Fang M, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Molecular Biology Reports. 2009;36(6):1475–1481.
    1. González-Reyes S, Fernández JM, González LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunology, Immunotherapy. 2011;60(2):217–226.
    1. Pandey R, Misra V, Misra SP, Dwivedi M, Kumar A, Tiwari BK. Helicobacter pylori and gastric cancer. Asian Pacific Journal of Cancer Prevention. 2010;11(3):583–588.
    1. Ogawa T, Asai Y, Sakai Y, et al. Endotoxic and immunobiological activities of a chemically synthesized lipid A of Helicobacter pylori strain 206-1. FEMS Immunology and Medical Microbiology. 2003;36(1-2):1–7.
    1. Yokota SI, Okabayashi T, Rehli M, Fujii N, Amano KI. Helicobacter pylori lipopolysaccharides upregulate Toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infection and Immunity. 2010;78(1):468–476.
    1. Su B, Ceponis PJM, Lebel S, Huynh H, Sherman PM. Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infection and Immunity. 2003;71(6):3496–3502.
    1. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29(2):206–217.
    1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535.
    1. Fukata M, Hernandez Y, Conduah D, et al. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflammatory Bowel Diseases. 2009;15(7):997–1006.
    1. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133(6):1869–e2.
    1. Greenhough A, Smartt HJM, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377–386.
    1. Hernandez Y, Sotolongo J, Breglio K, et al. The role of prostaglandin E2 (PGE 2) in Toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterology. 2010;10, article 82
    1. Cammarota R, Bertolini V, Pennesi G, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. Journal of Translational Medicine. 2010;8, article 112
    1. Starska K, Forma E, Lewy-Trenda I, et al. The expression of SOCS1 and TLR4-NFκB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma. Folia Histochemica et Cytobiologica. 2009;47(3):401–410.
    1. Wang EL, Qian ZR, Nakasono M, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. British Journal of Cancer. 2010;102(5):908–915.
    1. Earl TM, Nicoud IB, Pierce JM, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Annals of Surgical Oncology. 2009;16(4):1043–1050.
    1. Hua D, Liu MY, Cheng ZD, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Molecular Immunology. 2009;46(15):2876–2884.
    1. Gatti G, Quintar AA, Andreani V, et al. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate. 2009;69(13):1387–1397.
    1. Kundu SD, Lee C, Billips BK, et al. The Toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate. 2008;68(2):223–229.
    1. Yu L, Wang L, Li M, Zhong J, Wang Z, Chen S. Expression of Toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunology, Immunotherapy. 2010;59(7):1021–1028.
    1. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. British Journal of Cancer. 1999;81(8):1311–1317.
    1. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-B-dependent activation of the urokinase plasminogen activator system. British Journal of Cancer. 2009;100(10):1589–1602.
    1. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the Toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(12):2275–2281.
    1. Ji YY, Liu JT, Liu N, Wang ZD, Liu CH. PPARα activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway. Biochemical Pharmacology. 2009;78(9):1186–1197.
    1. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via Toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cellular Physiology and Biochemistry. 2009;23(4-6):265–276.
    1. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science. 2002;298(5595):1025–1029.
    1. Biragyn A, Coscia M, Nagashima K, Sanford M, Young HA, Olkhanud P. Murine β-defensin 2 promotes TLR-4/MyD88-mediated and NF-κB-dependent atypical death of APCs via activation of TNFR2. Journal of Leukocyte Biology. 2008;83(4):998–1008.
    1. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. Journal of Clinical Investigation. 2005;115(8):2223–2233.
    1. Babelova A, Moreth K, Tsalastra-Greul W, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. Journal of Biological Chemistry. 2009;284(36):24035–24048.
    1. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. Journal of Leukocyte Biology. 2009;86(3):557–566.
    1. Fischer H, Ellström P, Ekström K, Gustafsson L, Gustafsson M, Svanborg C. Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cellular Microbiology. 2007;9(5):1239–1251.
    1. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. Journal of Immunology. 2001;167(5):2887–2894.
    1. Kuhns DB, Priel DAL, Gallin JI. Induction of human monocyte interleukin (IL)-8 by fibrinogen through the Toll-like receptor pathway. Inflammation. 2007;30(5):178–188.
    1. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. Journal of Biological Chemistry. 2001;276(13):10229–10233.
    1. Gondokaryono SP, Ushio H, Niyonsaba F, et al. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. Journal of Leukocyte Biology. 2007;82(3):657–665.
    1. Park JS, Svetkauskaite D, He Q, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry. 2004;279(9):7370–7377.
    1. Jong SP, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. American Journal of Physiology. 2006;290(3):C917–C924.
    1. Yu M, Wang H, Ding A, et al. HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174–179.
    1. Mittal D, Saccheri F, Vénéreau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. The EMBO Journal. 2010;29(13):2242–2252.
    1. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. Journal of Immunology. 2000;164(2):558–561.
    1. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70. Role of Toll-like receptor (TLR) 2 and TLR4. Journal of Biological Chemistry. 2002;277(17):15028–15034.
    1. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway. Journal of Biological Chemistry. 2002;277(17):15107–15112.
    1. de Graaf R, Kloppenburg G, Kitslaar PJHM, Bruggeman CA, Stassen F. Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes and Infection. 2006;8(7):1859–1865.
    1. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. Journal of Immunology. 2002;168(10):5233–5239.
    1. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. Journal of Experimental Medicine. 2002;195(1):99–111.
    1. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. Journal of Biological Chemistry. 2004;279(17):17079–17084.
    1. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Medicine. 2005;11(11):1173–1179.
    1. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. Journal of Biological Chemistry. 2007;282(25):18265–18275.
    1. Gariboldi S, Palazzo M, Zanobbio L, et al. Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of β-defensin 2 via TLR2 and TLR4. Journal of Immunology. 2008;181(3):2103–2110.
    1. Shimada M, Yanai Y, Okazaki T, et al. Hyaluronan fragments generated by sperm-secreted hyaluronidase stimulate cytokine/chemokine production via the TLR 2 and TLR4 pathway in cumulus cells of ovulated COCs, which may enhance fertilization. Development. 2008;135(11):2001–2011.
    1. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. Journal of Biological Chemistry. 2003;278(3):1561–1568.
    1. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(6):1213–1219.
    1. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: Toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circulation Research. 2009;104(2):210–218.
    1. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature Medicine. 2007;13(9):1042–1049.
    1. Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8: a role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. Journal of Biological Chemistry. 2003;278(32):29661–29666.
    1. Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235–249.
    1. Park HD, Lee Y, Oh YK, et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene. 2011;30:201–211.
    1. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? Journal of Leukocyte Biology. 2008;83(5):1174–1180.
    1. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation. 2006;116(11):3015–3025.
    1. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. Journal of Immunology. 2002;168(12):5989–5992.
    1. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nature Medicine. 2009;15(7):774–780.
    1. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? Journal of Leukocyte Biology. 2010;87(6):989–999.
    1. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology. 2010;28:367–388.
    1. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clinical Cancer Research. 2007;13(10):2836–2848.
    1. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine. 2007;13(9):1050–1059.
    1. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. Journal of Immunology. 2008;180(7):5067–5074.
    1. Tsan M-F. Heat shock proteins and high mobility group box 1 protein lack cytokine function. Journal of Leukocyte Biology. 2011;89(6):247–852.
    1. Hreggvidsdottir HS, Östberg T, Wähämaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. Journal of Leukocyte Biology. 2009;86(3):655–662.
    1. Lee HK, Dunzendorfer S, Soldau K, Tobias PS. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity. 2006;24(2):153–163.
    1. Baumann CL, Aspalter IM, Sharif O, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. Journal of Experimental Medicine. 2010;207(12):2689–2701.
    1. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249(4975):1431–1433.
    1. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. Journal of Experimental Medicine. 2001;194(6):863–869.
    1. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(7085):808–812.
    1. West MA, Wallin RPA, Matthews SP, et al. Enhanced dendritic cell antigen capture via Toll-like receptor-induced actin remodeling. Science. 2004;305(5687):1153–1157.
    1. Garrett WS, Chen LM, Kroschewski R, et al. Developmental control of endocytosis in dendritic cells by Cdc42. Cell. 2000;102(3):325–334.
    1. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from Toll-like receptors. Science. 2004;304(5673):1014–1018.
    1. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–426.
    1. Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunology. 2003;4(2):175–181.
    1. Pham TNN, Hong CY, Min JJ, et al. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. Experimental and Molecular Medicine. 2010;42(6):407–419.
    1. Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. International Journal of Urology. 2011;18(2):113–120.
    1. Tsuji S, Matsumoto M, Takeuchi O, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium boris bacillus Calmette-Guérin: involvement of Toll-like receptors. Infection and Immunity. 2000;68(12):6883–6890.
    1. Roux S, Apetoh L, Chalmin F, et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. Journal of Clinical Investigation. 2008;118(11):3751–3761.
    1. Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (Picibanil) and possible application to dendritic cell therapy. Anticancer Research. 2004;24(5C):3295–3301.
    1. Okamoto M, Oshikawa T, Tano T, et al. Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. Journal of the National Cancer Institute. 2003;95(4):316–326.
    1. Okamoto M, Oshikawa T, Tano T, et al. Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. Journal of Immunotherapy. 2006;29(1):78–86.
    1. North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. Journal of Experimental Medicine. 1986;164(5):1652–1666.
    1. Shigematsu A, Adachi Y, Koike-Kiriyama N, et al. Effects of low-dose irradiation on enhancement of immunity by dendritic cells. Journal of Radiation Research. 2007;48(1):51–55.
    1. Kim KW, Kim SH, Shin JG, et al. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. International Journal of Cancer. 2004;109(5):685–690.
    1. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation. 2007;117(8):2197–2204.
    1. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470(7335):543–550.
    1. Garin A, Meyer-Hermann M, Contie M, et al. Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity. 2010;33(1):84–95.
    1. El Shikh MEM, El Sayed RM, Wu Y, Szakal AK, Tew JG. TLR4 on follicular dendritic cells: an activation pathway that promotes accessory activity. Journal of Immunology. 2007;179(7):4444–4450.
    1. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628–1632.
    1. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Advances in Experimental Medicine and Biology. 2009;667:111–123.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa